Assessment of Implementation of the Automated Erythrocytapheresis in the Outcome of Egyptian Sickle Cell Disease Patients: Single Center Experience

About the study

Improvements of health infrastructure, preventive care and clinical treatment have reduced
the morbidity and mortality of sickle cell disease (SCD). However, SCD is still an increasing
national health problem, with increase longevity the chronic effect of sustained hemolysis
and episodic vaso-occlusive events and the recurrent episodes of ischemic reperfusion injury
drive the development of progressive end organ complications and cardiovascular, pulmonary,
neurological and renal systems are most commonly affected. Today there is hope for a cure
using hematopoietic stem cell transplantation (HSCT). However, at present; the procedure is
infrequently performed and very expensive. In this research we will assess the effect of
implementation of the automated erythrocytapheresis in the outcome of sickle cell disease in
single Egyptian center.

Study point of contact

Fatma SE Ebeid, MD
01095569596
dr.fatma_ebeid@yahoo.com

Locations

1 Egypt site

Age

2 to 30 Years

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Procedure

Compensation

Unknown

participation requirements

– Patient with sickle cell disease (HbS with other variant hemoglobin)

– Age from 2-30y old

participation restrictions

Patients with other hemoglobinopathy Patients younger than two years

Locations

  • Cairo, Non-US, Egypt, Faculty of Medicine, Ain Shams University, 11556 [Recruiting]
Last updated 2020-04-14